News

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

The Alzheimer’s Drug Discovery Foundation made 5 new investments through its Diagnostics Accelerator initiative, through which it has $50 million in commitments from leading scientific philanthropists such as Leonard A. Lauder, Bill Gates, Jeff Bezos, and MacKenzie Bezos.

Artificial intelligence unlocks new potential to expand neuroimaging tools and techniques available for disease detection and prevention.

Neurology News Network for the week ending May 16, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

The director of pediatric epilepsy and professor of neurology at Mayo Clinic detailed how care for patients with epilepsy has changed during the COVID-19 pandemic.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Frontera, MD.

A cross-sectional, case-control study’s findings imply that patients with epilepsy may be experiencing high rates of psychological distress amid the COVID-19 pandemic.

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.

Finkel discussed his new role at St. Jude Children’s Research Hospital, where he'll head up the new Center for Experimental Neurotherapeutics.

Evidence continues to increase on the neurological impacts of COVID-19 infection, with patients admitted to the intensive care unit (ICU) showing brain abnormalities on MRI scans.

Automated Imaging Differentiation in Parkinsonism (AID-P) outperformed both the Magnetic Resonance Parkinsonism Index and neurofilament light chain protein in differentiating PD from atypical parkinsonism.

Pharmazz, the developer of the endothelin-B receptor agonist, noted that it plans to move forward with an investigational new drug submission to the FDA for sovateltide.

The neurologist at the Barrow Neurological Institute spoke to the impact that social media and telemedicine have had on the medical community’s ability to stay connected and continue to provide care and support.

Amid swirling reports of associations between stroke and the novel coronavirus, as well as the impact the pandemic has had on stroke care, new recommendations to maintain care expectations have been suggested by a diverse group of stroke experts.

Avadel seeks to have its sodium oxybate agent be the first once-nightly therapy to address both excessive daytime sleepiness and cataplexy in patients with narcolepsy.